Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Phase 2
Completed
- Conditions
- Alzheimer's Disease or Vascular Dementia
- Interventions
- Drug: BAC treatmentDrug: Matched vehicle
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Charsire Biotechnology Corp.
- Target Recruit Count
- 80
- Registration Number
- NCT02886494
- Locations
- 🇺🇸
Clinical Research Consortium, Tempe, Arizona, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Woodland Research Northwest, LLC, Rogers, Arkansas, United States
BAC in Patient With Alzheimer's Disease or Vascular Dementia
Phase 2
Withdrawn
- Conditions
- Alzheimer's DiseaseVascular Dementia
- Interventions
- Other: BAC Matched VehicleDrug: BAC
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Charsire Biotechnology Corp.
- Registration Number
- NCT02467413
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
CSTC1 for Diabetic Foot Ulcers Phase II Study
Phase 2
Completed
- Conditions
- Diabetic Foot UlcerDiabetes MellitusWounds
- Interventions
- Drug: CSTC1 Matched vehicle
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Charsire Biotechnology Corp.
- Target Recruit Count
- 124
- Registration Number
- NCT01813305
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
News
No news found